Tuesday, 4 November 2025 at 11:00 - 12:00am CETIn connection with the publication of Coloplast’s interim financial results for FY 2024/25, to be released same day around 07.00am CET, Coloplast will ...

• On October 31, 2025 the Centers for Medicare & Medicaid Services in the US issued a final rule on the Medicare Physician Fee Schedule, which applies to physicians private office in the out-patient ...

Coloplast, a leading company within intimate healthcare, will invest around 100 million euros in a new manufacturing site in Portugal to support the company’s continued growth. The new manufacturing ...

In connection with the publication of Coloplast’s interim financial results for H1 2024/25, to be released same day around 07.30am CEST, Coloplast will host a conference call to present the financial ...

Coloplast announced today that it has completed the acquisition of Nine Continents Medical, Inc., an early stage company pioneering an implantable tibial nerve stimulation treatment for over-active ...

In relation to the launch of Coloplast’s new 5-year strategy, Impact4, the company announces a new financial ambition with organic revenue CAGR of 7-8% until FY 2029/30, growth in absolute EBIT* in ...

Coloplast launches new 2025 strategy and provides new long-term financial guidance of 7-9% organic revenue growth and an EBIT margin of more than 30% Coloplast will host a virtual Capital Markets Day ...

Coloplast announced it will acquire wound care product company Kerecis for $1.3 billion. The acquisition will give Coloplast an opportunity to “strategically strengthen [its] presence in the advanced ...

COPENHAGEN, July 7 (Reuters) - Coloplast (COLOb.CO), opens new tab has agreed to buy Iceland-based Kerecis, a biologic wound care firm that uses fish skin to develop tissue-transplant products, for up ...

Minneapolis-based Coloplast Corp. is paying $3 million to settle allegations that the company made illegal payments to cause thousands of senior citizens to switch to its bowel and bladder devices.

Coloplast's growth momentum and margins are declining, with recent operational missteps and weak demand, especially in China, weighing on results. Despite a strong market position and defensive ...